GCG and type 2 diabetes mellitus: Indeed, several randomized controlled trials have demonstrated that medications indicated for treatment of T2DM such as glucagon like peptide-1 (GLP-1) [14, 15] and sodium-glucose co-transporter 2 (SGLT-2) inhibitors [16, 17] can slow renal disease progression as well as reduce adverse CV outcomes.